In patients with venous thromboembolism taking oral anticoagulants, the case-fatality rate of major bleeding was 13.4% (95% CI, 9.4-17.4%) and intracranial bleeding was 1.15 per 100 patient-years.
Meta-Analysis
What is the case-fatality rate of major bleeding and the risk of intracranial bleeding in patients with venous thromboembolism receiving oral anticoagulant therapy?
The clinical impact of anticoagulant-related major bleeding in VTE patients is considerable, with a 13.4% case-fatality rate for major bleeding, which should inform long-term anticoagulation decisions.
BACKGROUND: Clinicians should consider the clinical impact of anticoagulant-related bleeding when deciding on the duration of anticoagulant therapy in patients with venous thromboembolism. PURPOSE: To provide reliable estimates of the clinical impact of anticoagulant-related bleeding, defined as the case-fatality rate of major bleeding and the risk for intracranial bleeding. DATA SOURCES: MEDLINE (January 1989 to May 2003), Cochrane Controlled Trial Registry, thromboembolism experts, and reference lists; English-language literature only. STUDY SELECTION: Randomized, controlled trials and prospective cohort studies that investigated patients with venous thromboembolism who received oral anticoagulant therapy (target international normalized ratio, 2.0 to 3.0) for at least 3 months and that reported major bleeding and death as primary study outcomes. DATA EXTRACTION: Two reviewers independently extracted data on the number of anticoagulant-related major and intracranial bleeding episodes and on whether these events were fatal or nonfatal. DATA SYNTHESIS: The authors analyzed 33 studies involving 4374 patient-years of oral anticoagulant therapy. For all patients, the case-fatality rate of major bleeding was 13.4% (95% CI, 9.4% to 17.4%) and the rate of intracranial bleeding was 1.15 per 100 patient-years (CI, 1.14 to 1.16 per 100 patient-years). For patients who received anticoagulant therapy for more than 3 months, the case-fatality rate of major bleeding was 9.1% (CI, 2.5% to 21.7%), and the rate of intracranial bleeding was 0.65 per 100 patient-years (CI, 0.63 to 0.68 per 100 patient-years) after the initial 3 months of anticoagulation. CONCLUSION: The clinical impact of anticoagulant-related major bleeding in patients with venous thromboembolism is considerable, and clinicians should take this into account when deciding whether to continue long-term oral anticoagulant therapy in an individual patient.
Linkins et al. (2003) conducted a meta-analysis in venous thromboembolism. Oral anticoagulant therapy was evaluated on case-fatality rate of major bleeding (95% CI 9.4-17.4). In patients with venous thromboembolism taking oral anticoagulants, the case-fatality rate of major bleeding was 13.4% (95% CI, 9.4-17.4%) and intracranial bleeding was 1.15 per 100 patient-years.